

# CORTICAL LAYERS

The cerebral cortex is the part of the human brain that undergoes the most profound evolutionary changes and serves as a substrate for higher cognitive functions.

During embryonal development, six distinct layers are generated from the progenitors of the neocortical germinal zone. In the adult brain, the different cortical layers are defined based on morphologically and functionally divergent neurons.


The six cortical layers are generated during embryonal development in a strictly regulated manner.

Following the formation of the cortical plate, the deeper layers neurons (including layers V and VI) and the upper layers neurons (layers II-IV) are generated.

Glial cells, including astrocytes and oligodendrocytes, are then generated at the latest stages of cortical development.


Neocortical neurogenesis depends on several transcriptional factors. For instance, LHX2 and PAX6 play a crucial role in the specification of neocortical progenitors, giving rise to the projection neurons. In addition, MEF2C is another transcription factor essential for normal neural development and spatial distribution in the neocortex.

Our selected markers for the cortical layers provide a useful tool for studying the development, the functional neuroanatomy and the pathology of the cerebral cortex.



**Figure 1.** Tissue expression of transcription factors involved in the development of the cerebral cortex: LHX2, PAX6 and MEF2C.

**A.** Immunohistochemical staining with Anti-LHX2 antibody (AMAb91404) shows strong immunoreactivity in the developing cortex and sensory organs of mouse embryo E11. **B.** PAX6 expression is detected in both the developing brain and sensory organs, including the eye (**C**) using the monoclonal antibody AMAb91372. **D.** MEF2C is primarily expressed in the upper layers of the developing cortex, as shown by the anti-MEF2C antibody (AMAb90728) in mouse embryo E14.



**Figure 2.** Laminar distribution of protein expression profiles in the cerebral cortex of rat.

**A,F.** RELN immunoreactivity is mainly detected in the neuropil of layer I (AMAb91365). **B,G.** CUX1 expression is visible in layers II-IV (HPA003277). **C,H.** BCL11B (CTIP2) is expressed primarily in layers V and VI (HPA049117). **D,I.** Layer VI neurons show strong expression of FOXP2 (AMAb91362). **E,J.** Layer VIb can be identified by the presence of CTGF immunoreactivity (AMAb91366).


## Anatomic and functional diversity of neurons in the six cortical layers

In the mature neocortex, neurons of different layers display anatomical and functional diversity, including cell morphology, physiological properties, and anatomical connections.

Neurons of layers II/III, along with a subset of neurons of layer V, contribute mostly to intracortical connections, including the callosal projections to the contralateral cerebral hemisphere.

Layer V corticofugal neurons target the midbrain, hindbrain, and spinal cord, while layer VI neurons project mainly to the thalamus.

Protein expression profiles differ in neurons of various layers: for example, upper layers neurons can be identified by expression of CUX1 and POU3F2 (BRN2); the neurons of layer V express BCL11B (CTIP2), while neurons of layer VI express FOXP2. The laminar distribution of these and other markers in the human and rat cortex is shown in Figures 2-6.



**Figure 3. Laminar structure of the rat cerebral cortex.**


Laminar structure of cerebral cortex of rat as shown by multiplexed immunofluorescence using the Anti-CUX1 (HPA003277, blue), the Anti-NECAB1 (AMAb90800, green), and the Anti-FOXP2 (AMAb91362, red) antibodies. Note that CUX1 is mainly expressed in layers II-III, NECAB1 shows the most robust expression in layer IV neurons, while FOXP2 is primarily present in layer VI neurons.

**Table 1.**  
Selected markers from Atlas Antibodies targeting cortical layers for tissue and cell analysis.


| Cortical Layer       | Product Name        | Product number | Clonality  | Validated Applications | Sequence Identity (Mouse/Rat) |
|----------------------|---------------------|----------------|------------|------------------------|-------------------------------|
| Layer 1              | Anti-RELN           | AMAb91365      | Monoclonal | IHC                    | 90%/94%                       |
| Layer 1              | Anti-RELN           | HPA046512      | Polyclonal | ICC-IF                 | 90%/94%                       |
| Layer 2/3            | Anti-RASGRF2        | HPA018679      | Polyclonal | IHC                    | 72%/71%                       |
| Layer 2/3            | Anti-CALB1          | HPA023099      | Polyclonal | IHC*, WB, ICC-IF       | 98%/99%                       |
| Layer 2/3-4          | Anti-CUX1           | AMAb91352      | Monoclonal | IHC, ICC-IF            | 72%/74%                       |
| Layer 2/3-4          | Anti-CUX1           | AMAb91353      | Monoclonal | IHC, ICC-IF            | 72%/74%                       |
| Layer 2/3-4          | Anti-CUX1           | HPA003277      | Polyclonal | IHC                    | 72%/74%                       |
| Layers 2/3, 4 and 5b | Anti-POU3F2 (BRN2)  | HPA056261      | Polyclonal | ICC-IF                 | 100%/100%                     |
| Layers 2/3, 4 and 5b | Anti-POU3F2 (BRN2)  | AMAb91406      | Monoclonal | IHC, WB*, ICC-IF       | 100%/100%                     |
| Layers 2/3, 4 and 5b | Anti-POU3F2 (BRN2)  | AMAb91407      | Monoclonal | IHC, ICC-IF            | 100%/100%                     |
| Layer 2-4 (mainly 4) | Anti-NECAB1         | AMAb90798      | Monoclonal | IHC, WB                | 98%/98%                       |
| Layer 2-4 (mainly 4) | Anti-NECAB1         | AMAb90800      | Monoclonal | IHC, WB                | 98%/98%                       |
| Layer 2-4 (mainly 4) | Anti-NECAB1         | AMAb90801      | Monoclonal | IHC, WB                | 98%/98%                       |
| Layer 2-4 (mainly 4) | Anti-NECAB1         | HPA023629      | Polyclonal | IHC*, WB*              | 98%/98%                       |
| Layer 2-4 (mainly 4) | Anti-NECAB1         | HPA031262      | Polyclonal | IHC*, WB*              | 97%/98%                       |
| Layer 5              | Anti-PCP4           | HPA005792      | Polyclonal | IHC*                   | 96%/96%                       |
| Layer 5              | Anti-CNTN6          | HPA016645      | Polyclonal | IHC                    | 86%/84%                       |
| Layers 5-6           | Anti-BCL11B (CTIP2) | HPA049117      | Polyclonal | IHC*, ICC-IF           | 96%/98%                       |
| Layer 6              | Anti-FOXP2          | AMAb91361      | Monoclonal | IHC, ICC-IF            | 99%/97%                       |
| Layer 6              | Anti-FOXP2          | AMAb91362      | Monoclonal | IHC, ICC-IF            | 99%/97%                       |
| Layer 6              | Anti-FOXP2          | HPA000382      | Polyclonal | IHC, WB                | 99%/97%                       |
| Layer 6              | Anti-TLE4           | HPA065357      | Polyclonal | ICC-IF                 | 100%/100%                     |
| Layer 6b             | Anti-CTGF           | AMAb91366      | Monoclonal | IHC, WB                | 96%/97%                       |
| Layer 6b             | Anti-CTGF           | HPA031075      | Polyclonal | IHC, WB, ICC-IF        | 96%/97%                       |

\* Products with enhanced validation for indicated applications






**Figure 4.**  
**A,B.** Immunohistochemical staining of rat brain using the Anti-FOXP2 monoclonal antibody (AMAb91362) shows nuclear immunoreactivity in cortical layer 6 neurons, as well as in caudato-putamen, in brown.



**Figure 5.**  
**A.** Immunohistochemical staining of human cerebral cortex using the Anti-NECAB1 polyclonal antibody (HPA031262) shows strong cytoplasmic immunoreactivity in neurons, in brown, and no positivity in human colon, as expected (**B**).



**Figure 6.**  
**A.** Immunohistochemical staining of the mouse cerebral cortex using the Anti-POU3F2 monoclonal antibody (AMAb91407) shows moderate to strong nuclear positivity in neurons in layers 2-5, and no positivity in neurons of layer 6, as expected (**B**).

## VERY RELIABLE ANTIBODIES

Atlas Antibodies manufactures and provides over 21,000 highly validated monoclonal and polyclonal primary antibodies and control antigens targeting the majority of human proteins for tissue and cell analysis to explore and accelerate research in biology, pathology, and medicine. The portfolio covers different research areas such as neuroscience, cancer, cell biology, stem cell & development. All our products are rigorously evaluated for specificity, reproducibility and performance and characterized for use in IHC, WB, and ICC-IF. Enhanced validation is applied as an extra level of security of antibody specificity in a defined context. Available as 25 µL and 100 µL unit size.

## CREATED BY THE HUMAN PROTEIN ATLAS

With our roots in the Human Protein Atlas project, an integration of antibody-based imaging, proteomics, and transcriptomics, our antibodies are affinity-purified, reproducible, selective, and specific for their target proteins through our enhanced validation process. Our Triple A Polyclonals™ are developed within the Human Protein Atlas project.

## VALIDATED BY ENHANCED VALIDATION

We take great care to validate our antibodies in IHC, WB, and ICC-IF. Our antibodies are validated in all major human tissues and organs and 20 cancer tissues. Each antibody is supported by over 500 staining images. As an additional layer of security, we perform Enhanced Validation. By using 5 different enhanced validation methods we validate our antibodies for each combination of protein, sample, and application. Discover our Triple A Polyclonals™ and PrecisA Monoclonals™ antibodies targeting the majority of human proteins in cells, tissues, and organs.

## EVIDENCED BY SCIENCE

Made by researchers for researchers our products are used worldwide and referenced in 1000s of scientific peer-reviewed papers.

## WE SUPPORT YOUR RESEARCH

Our scientific content and newsletter provide you with timely information about new product releases, research highlights, and much more. In addition, from our website you can download informative white papers, protocols, guides, posters, infographics, roundups of recent research papers, read blog posts and interviews.

## HOW TO BUY OUR PRODUCTS

Our products are available worldwide. We deliver to all destinations in Europe (excluding Russia), US, Canada, Australia, New Zealand and Israel. We expand our offering through trusted partners worldwide.

You can [shop our full catalog online](#) or [find your local supplier](#).



### Atlas Antibodies Advanced Polyclonals.

Triple A Polyclonals™ are rabbit polyclonal primary antibodies developed within the Human Protein Atlas project. IHC characterization data from 44 normal and 20 cancer tissues is available on the Human Protein Atlas portal.



### Precise. Accurate. Targeted.

PrecisA Monoclonals™ are mouse monoclonal primary antibodies developed against a number of carefully selected targets. Clones are selected to recognize only unique non-overlapping epitopes and isotypes.

## PrEST Antigens

### Recombinant protein fragments

PrEST Antigens™ are used as immunogens for the generation of Triple A Polyclonals and PrecisA Monoclonals.



In addition to the extensive validation and characterization always performed for our antibodies, we conduct application-specific **enhanced validation** to secure the antibody specificity in a defined context.



Visit us: [atlasantibodies.com](https://atlasantibodies.com)

Follow us: [@atlasantibodies](https://twitter.com/atlasantibodies)

Contact us: [contact@atlasantibodies.com](mailto:contact@atlasantibodies.com)

Atlas Antibodies logo, Triple A Polyclonals, PrecisA Monoclonals, and PrEST Antigens are trademarks or registered trademarks of Atlas Antibodies AB. All other trademarks are the property of their respective owners. Products are for research use only. Not for use in diagnostic procedures. © Atlas Antibodies AB 2022.

023\_20220705



**Atlas Antibodies AB**  
Voltavägen 13A  
16869 Bromma, Sweden  
[atlasantibodies.com](https://atlasantibodies.com)

**Phone** +46(0)8 54 59 58 50  
[contact@atlasantibodies.com](mailto:contact@atlasantibodies.com)  
[order@atlasantibodies.com](mailto:order@atlasantibodies.com)  
[support@atlasantibodies.com](mailto:support@atlasantibodies.com)